2026

Bryce, A. S. et al. (2026) Morphospatial profiling of cancer-associated fibroblasts reveals architectural subtypes of pancreatic ductal adenocarcinoma. bioRxiv, (doi: 10.64898/2026.02.06.704414)

2025

Knox, J. J. et al. (2025) PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 43(31), pp. 3355-3368. (doi: 10.1200/JCO-25-00436) (PMID:40929627)

Herbert, Katharine J. ORCID: https://orcid.org/0000-0001-9437-0253, Upstill-Goddard, Rosie, Dreyer, Stephan B., Rebus, Selma, Pilarsky, Christian, Debabrata, Mukhopadhyay, Lord, Christopher J., Biankin, Andrew V. ORCID: https://orcid.org/0000-0002-0362-5597, Froeling, Fieke E.M. ORCID: https://orcid.org/0000-0002-8653-8164 and Chang, David K. ORCID: https://orcid.org/0000-0002-4821-3078 (2025) Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma. British Journal of Cancer, 133(3), pp. 381-393. (doi: 10.1038/s41416-025-03051-z) (PMID:40442403)

Kocher, H. M. et al. (2025) Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2. BMC Cancer, 25(1), 106. (doi: 10.1186/s12885-024-13333-z) (PMID:39833722) (PMCID:PMC11748870)

2024

Pea, A. et al. (2024) Clonal evolutionary analysis reveals patterns of malignant transformation in pancreatic cancer from Intraductal Papillary Mucinous IPMN Neoplasms (IPMN). bioRxiv, August 6. (doi: 10.1101/2024.08.02.606217)

Bryce, Adam ORCID: https://orcid.org/0000-0003-0253-9723, Dreyer, Stephan, Dolan, Ross ORCID: https://orcid.org/0000-0002-5272-5906, Froeling, Fieke ORCID: https://orcid.org/0000-0002-8653-8164 and Chang, David ORCID: https://orcid.org/0000-0002-4821-3078 (2024) Host phenotypic adversity independently predicts progression to resection in neoadjuvantly-treated pancreatic cancer. 42nd Congress of the European Society of Surgical Oncology, Florence, Italy, 25-27 Oct 2023. (doi: 10.1016/j.ejso.2023.107753)

2023

Chung, Taemoon, Garcia, Libia, Swamynathan, Manojit M., Froeling, Fieke E.M. ORCID: https://orcid.org/0000-0002-8653-8164, Trotman, Lloyd C., Tuveson, David A. and Lyons, Scott K. (2023) Internally controlled and dynamic optical measures of functional tumor biology. Analytical Chemistry, 95(13), pp. 5661-5670. (doi: 10.1021/acs.analchem.2c05450) (PMID:36952386) (PMCID:PMC10077328)

2022

Bryce, Adam S. ORCID: https://orcid.org/0000-0003-0253-9723, Dreyer, Stephan B., Froeling, Fieke E.M. ORCID: https://orcid.org/0000-0002-8653-8164 and Chang, David K. ORCID: https://orcid.org/0000-0002-4821-3078 (2022) Exploring the biology of cancer-associated fibroblasts in pancreatic cancer. Cancers, 14(21), 5302. (doi: 10.3390/cancers14215302) (PMID:36358721) (PMCID:PMC9659154)

2021

Casolino, R. et al. (2021) Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. Journal of Clinical Oncology, 39(23), pp. 2617-2631. (doi: 10.1200/JCO.20.03238) (PMID:34197182) (PMCID:PMC8331063)

Casolino, R. et al. (2021) Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Annals of Oncology, 32(2), pp. 183-196. (doi: 10.1016/j.annonc.2020.11.013) (PMID:33248227) (PMCID:PMC7840891)

Froeling, Fieke E.M. ORCID: https://orcid.org/0000-0002-8653-8164, Casolino, Raffaella, Pea, Antonio, Biankin, Andrew V. ORCID: https://orcid.org/0000-0002-0362-5597 and Chang, David K. ORCID: https://orcid.org/0000-0002-4821-3078 (2021) Molecular subtyping and precision medicine for pancreatic cancer. Journal of Clinical Medicine, 10(1), 149. (doi: 10.3390/jcm10010149) (PMID:33406790) (PMCID:PMC7794969)

2020

Kocher, H. M. et al. (2020) Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Nature Communications, 11(1), 4841. (doi: 10.1038/s41467-020-18636-w) (PMID:32973176) (PMCID:PMC7518421)

Articles

Bryce, A. S. et al. (2026) Morphospatial profiling of cancer-associated fibroblasts reveals architectural subtypes of pancreatic ductal adenocarcinoma. bioRxiv, (doi: 10.64898/2026.02.06.704414)

Knox, J. J. et al. (2025) PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 43(31), pp. 3355-3368. (doi: 10.1200/JCO-25-00436) (PMID:40929627)

Herbert, Katharine J. ORCID: https://orcid.org/0000-0001-9437-0253, Upstill-Goddard, Rosie, Dreyer, Stephan B., Rebus, Selma, Pilarsky, Christian, Debabrata, Mukhopadhyay, Lord, Christopher J., Biankin, Andrew V. ORCID: https://orcid.org/0000-0002-0362-5597, Froeling, Fieke E.M. ORCID: https://orcid.org/0000-0002-8653-8164 and Chang, David K. ORCID: https://orcid.org/0000-0002-4821-3078 (2025) Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma. British Journal of Cancer, 133(3), pp. 381-393. (doi: 10.1038/s41416-025-03051-z) (PMID:40442403)

Kocher, H. M. et al. (2025) Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2. BMC Cancer, 25(1), 106. (doi: 10.1186/s12885-024-13333-z) (PMID:39833722) (PMCID:PMC11748870)

Pea, A. et al. (2024) Clonal evolutionary analysis reveals patterns of malignant transformation in pancreatic cancer from Intraductal Papillary Mucinous IPMN Neoplasms (IPMN). bioRxiv, August 6. (doi: 10.1101/2024.08.02.606217)

Chung, Taemoon, Garcia, Libia, Swamynathan, Manojit M., Froeling, Fieke E.M. ORCID: https://orcid.org/0000-0002-8653-8164, Trotman, Lloyd C., Tuveson, David A. and Lyons, Scott K. (2023) Internally controlled and dynamic optical measures of functional tumor biology. Analytical Chemistry, 95(13), pp. 5661-5670. (doi: 10.1021/acs.analchem.2c05450) (PMID:36952386) (PMCID:PMC10077328)

Bryce, Adam S. ORCID: https://orcid.org/0000-0003-0253-9723, Dreyer, Stephan B., Froeling, Fieke E.M. ORCID: https://orcid.org/0000-0002-8653-8164 and Chang, David K. ORCID: https://orcid.org/0000-0002-4821-3078 (2022) Exploring the biology of cancer-associated fibroblasts in pancreatic cancer. Cancers, 14(21), 5302. (doi: 10.3390/cancers14215302) (PMID:36358721) (PMCID:PMC9659154)

Casolino, R. et al. (2021) Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. Journal of Clinical Oncology, 39(23), pp. 2617-2631. (doi: 10.1200/JCO.20.03238) (PMID:34197182) (PMCID:PMC8331063)

Casolino, R. et al. (2021) Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Annals of Oncology, 32(2), pp. 183-196. (doi: 10.1016/j.annonc.2020.11.013) (PMID:33248227) (PMCID:PMC7840891)

Froeling, Fieke E.M. ORCID: https://orcid.org/0000-0002-8653-8164, Casolino, Raffaella, Pea, Antonio, Biankin, Andrew V. ORCID: https://orcid.org/0000-0002-0362-5597 and Chang, David K. ORCID: https://orcid.org/0000-0002-4821-3078 (2021) Molecular subtyping and precision medicine for pancreatic cancer. Journal of Clinical Medicine, 10(1), 149. (doi: 10.3390/jcm10010149) (PMID:33406790) (PMCID:PMC7794969)

Kocher, H. M. et al. (2020) Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Nature Communications, 11(1), 4841. (doi: 10.1038/s41467-020-18636-w) (PMID:32973176) (PMCID:PMC7518421)

Conference or Workshop Item

Bryce, Adam ORCID: https://orcid.org/0000-0003-0253-9723, Dreyer, Stephan, Dolan, Ross ORCID: https://orcid.org/0000-0002-5272-5906, Froeling, Fieke ORCID: https://orcid.org/0000-0002-8653-8164 and Chang, David ORCID: https://orcid.org/0000-0002-4821-3078 (2024) Host phenotypic adversity independently predicts progression to resection in neoadjuvantly-treated pancreatic cancer. 42nd Congress of the European Society of Surgical Oncology, Florence, Italy, 25-27 Oct 2023. (doi: 10.1016/j.ejso.2023.107753)